Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

Carlo Visco, Gianpaolo Nadali, Theodoros P. Vassilakopoulos, Valeria Bonfante, Simonetta Viviani, Alessandro M. Gianni, Massimo Federico, Stefano Luminari, Prema Peethambaram, Thomas Elmer Witzig, Gerassimos Pangalis, Fernando Cabanillas, L. Jeffrey Medeiros, Andreas H. Sarris, Giovanni Pizzolo

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Methods: We identified 321 previously untreated patients with cHL who presented to the participating centers between 1985 and 2002, and had serum samples available for the determination of sCD30 levels. Results: With a median follow-up of 72 months, the actuarial 5-year overall survival was 82%, and failure-free survival (FFS) was 71%. The median serum level of sCD30 was 65 U/mL (range: 1-2230), and was significantly higher (P < 0.0001) when compared with a group of 113 healthy controls (4 U/mL, range: 0-20). Increasing level of sCD30 was associated with a continuous worsening of FFS and OS, and patients with sCD30 ≥200 U/mL had a 5-year FFS of 39%. With multivariate analysis, sCD30, Ann Arbor stage, and lactic acid dehydrogenase were significant independent factors in terms of FFS. The association of the above-mentioned three independent prognostic variables could discriminate 22% of patients with 5-year FFS of 40%. Conclusions: Our data confirm the independent prognostic role of sCD30 in identifying the patients with high risk of treatment failure, and show that its association with other variables can recognize patients with FFS considerably lower than 50%.

Original languageEnglish (US)
Pages (from-to)387-394
Number of pages8
JournalEuropean Journal of Haematology
Volume77
Issue number5
DOIs
StatePublished - Nov 2006

Fingerprint

Hodgkin Disease
Survival
Serum
Dacarbazine
Vinblastine
Bleomycin
Treatment Failure
Doxorubicin
Lactic Acid
Oxidoreductases
Multivariate Analysis

Keywords

  • Classical Hodgkin's lymphoma
  • Lactic acid dehydrogenase
  • Prognosis
  • sCD30
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. / Visco, Carlo; Nadali, Gianpaolo; Vassilakopoulos, Theodoros P.; Bonfante, Valeria; Viviani, Simonetta; Gianni, Alessandro M.; Federico, Massimo; Luminari, Stefano; Peethambaram, Prema; Witzig, Thomas Elmer; Pangalis, Gerassimos; Cabanillas, Fernando; Medeiros, L. Jeffrey; Sarris, Andreas H.; Pizzolo, Giovanni.

In: European Journal of Haematology, Vol. 77, No. 5, 11.2006, p. 387-394.

Research output: Contribution to journalArticle

Visco, C, Nadali, G, Vassilakopoulos, TP, Bonfante, V, Viviani, S, Gianni, AM, Federico, M, Luminari, S, Peethambaram, P, Witzig, TE, Pangalis, G, Cabanillas, F, Medeiros, LJ, Sarris, AH & Pizzolo, G 2006, 'Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis', European Journal of Haematology, vol. 77, no. 5, pp. 387-394. https://doi.org/10.1111/j.1600-0609.2006.00725.x
Visco, Carlo ; Nadali, Gianpaolo ; Vassilakopoulos, Theodoros P. ; Bonfante, Valeria ; Viviani, Simonetta ; Gianni, Alessandro M. ; Federico, Massimo ; Luminari, Stefano ; Peethambaram, Prema ; Witzig, Thomas Elmer ; Pangalis, Gerassimos ; Cabanillas, Fernando ; Medeiros, L. Jeffrey ; Sarris, Andreas H. ; Pizzolo, Giovanni. / Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. In: European Journal of Haematology. 2006 ; Vol. 77, No. 5. pp. 387-394.
@article{180a6cdaa4cf46cb831a05a2f740000d,
title = "Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis",
abstract = "Objectives: To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Methods: We identified 321 previously untreated patients with cHL who presented to the participating centers between 1985 and 2002, and had serum samples available for the determination of sCD30 levels. Results: With a median follow-up of 72 months, the actuarial 5-year overall survival was 82{\%}, and failure-free survival (FFS) was 71{\%}. The median serum level of sCD30 was 65 U/mL (range: 1-2230), and was significantly higher (P < 0.0001) when compared with a group of 113 healthy controls (4 U/mL, range: 0-20). Increasing level of sCD30 was associated with a continuous worsening of FFS and OS, and patients with sCD30 ≥200 U/mL had a 5-year FFS of 39{\%}. With multivariate analysis, sCD30, Ann Arbor stage, and lactic acid dehydrogenase were significant independent factors in terms of FFS. The association of the above-mentioned three independent prognostic variables could discriminate 22{\%} of patients with 5-year FFS of 40{\%}. Conclusions: Our data confirm the independent prognostic role of sCD30 in identifying the patients with high risk of treatment failure, and show that its association with other variables can recognize patients with FFS considerably lower than 50{\%}.",
keywords = "Classical Hodgkin's lymphoma, Lactic acid dehydrogenase, Prognosis, sCD30, Survival",
author = "Carlo Visco and Gianpaolo Nadali and Vassilakopoulos, {Theodoros P.} and Valeria Bonfante and Simonetta Viviani and Gianni, {Alessandro M.} and Massimo Federico and Stefano Luminari and Prema Peethambaram and Witzig, {Thomas Elmer} and Gerassimos Pangalis and Fernando Cabanillas and Medeiros, {L. Jeffrey} and Sarris, {Andreas H.} and Giovanni Pizzolo",
year = "2006",
month = "11",
doi = "10.1111/j.1600-0609.2006.00725.x",
language = "English (US)",
volume = "77",
pages = "387--394",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

AU - Visco, Carlo

AU - Nadali, Gianpaolo

AU - Vassilakopoulos, Theodoros P.

AU - Bonfante, Valeria

AU - Viviani, Simonetta

AU - Gianni, Alessandro M.

AU - Federico, Massimo

AU - Luminari, Stefano

AU - Peethambaram, Prema

AU - Witzig, Thomas Elmer

AU - Pangalis, Gerassimos

AU - Cabanillas, Fernando

AU - Medeiros, L. Jeffrey

AU - Sarris, Andreas H.

AU - Pizzolo, Giovanni

PY - 2006/11

Y1 - 2006/11

N2 - Objectives: To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Methods: We identified 321 previously untreated patients with cHL who presented to the participating centers between 1985 and 2002, and had serum samples available for the determination of sCD30 levels. Results: With a median follow-up of 72 months, the actuarial 5-year overall survival was 82%, and failure-free survival (FFS) was 71%. The median serum level of sCD30 was 65 U/mL (range: 1-2230), and was significantly higher (P < 0.0001) when compared with a group of 113 healthy controls (4 U/mL, range: 0-20). Increasing level of sCD30 was associated with a continuous worsening of FFS and OS, and patients with sCD30 ≥200 U/mL had a 5-year FFS of 39%. With multivariate analysis, sCD30, Ann Arbor stage, and lactic acid dehydrogenase were significant independent factors in terms of FFS. The association of the above-mentioned three independent prognostic variables could discriminate 22% of patients with 5-year FFS of 40%. Conclusions: Our data confirm the independent prognostic role of sCD30 in identifying the patients with high risk of treatment failure, and show that its association with other variables can recognize patients with FFS considerably lower than 50%.

AB - Objectives: To evaluate the prognostic role of pretreatment serum levels of soluble CD30 (sCD30) in patients with advanced stage classical Hodgkin's lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Methods: We identified 321 previously untreated patients with cHL who presented to the participating centers between 1985 and 2002, and had serum samples available for the determination of sCD30 levels. Results: With a median follow-up of 72 months, the actuarial 5-year overall survival was 82%, and failure-free survival (FFS) was 71%. The median serum level of sCD30 was 65 U/mL (range: 1-2230), and was significantly higher (P < 0.0001) when compared with a group of 113 healthy controls (4 U/mL, range: 0-20). Increasing level of sCD30 was associated with a continuous worsening of FFS and OS, and patients with sCD30 ≥200 U/mL had a 5-year FFS of 39%. With multivariate analysis, sCD30, Ann Arbor stage, and lactic acid dehydrogenase were significant independent factors in terms of FFS. The association of the above-mentioned three independent prognostic variables could discriminate 22% of patients with 5-year FFS of 40%. Conclusions: Our data confirm the independent prognostic role of sCD30 in identifying the patients with high risk of treatment failure, and show that its association with other variables can recognize patients with FFS considerably lower than 50%.

KW - Classical Hodgkin's lymphoma

KW - Lactic acid dehydrogenase

KW - Prognosis

KW - sCD30

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33749262442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749262442&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2006.00725.x

DO - 10.1111/j.1600-0609.2006.00725.x

M3 - Article

VL - 77

SP - 387

EP - 394

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 5

ER -